069 – AstraZeneca Rivals Moderna in Race to Successful SARS-CoV-2 Vaccine with ChAdOx1 nCov-19!

AstraZeneca (#AZN) publishes their Phase 1/2 data of their SARS-CoV-2 vaccine candidate ChAdOx1 nCov-19. I go through the side effects, humoral efficacy and cellular response and contrast the results to Moderna’s (#MRNA) candidate, MRNA-1273. I also talk about a few other biotech companies, notably: $TRIL, $VKTX and $BLUE. If you want to help the show, […]

068 – Biotech Round Up (RGNX, ODT, AXGT, CBIO) and Moderna Phase 1 Interim Publication

In this episode I go through a few different biotech companies that I have touched on in the past (some which I have current positions). I close out the episode talking about Moderna and the publication of the interim data from their Phase 1 study for MRNA-1273, a vaccine for Sars-CoV 2. If you want […]

067 – Intercept Pharma’s Ocaliva Fails to get Approval in NASH while FGFs Compete for Best in Class

After delays in scheduling their advisory committee meeting, the FDA finally sends Intercept Pharma ($ICPT) a Complete Response Letter. In the letter, the FDA says that the benefits of Ocaliva shown via surrogate histopathologic endpoints do not sufficiently outweight the risks to support accelerated approval. Intercept will likely need to collect outcomes data to finally […]

066 – Actinium Pharma’s Transformative Radiation Treatment. KPTI’s Selinexor Approved for DLBCL!

Actinium Pharma (#ATNM) is commercializing Antibody-Radiation Conjugates (ARC) for the treatment of diseases that require conditioning regimens (Bone Marrow Transplant, Stem Cell Transplant, Adoptive Cell Therapies). The current state of total body irradiation leaves patients with significant side effects and excludes a large demographic due to potential lethality of the conditioning treatment. ATNM is testing […]

065 – Are Iovance’s Buyout Hopes SHATTERED?? Karyopharm Moves to Expand Selinexor’s Label

Iovance (#IOVA) confirms a profound effect of LN-144 in metastatic melanoma with interim data from their 4th cohort. They also showed early data in NSCLC, which is an important indication for the company’s future. Karyopharm’s (#KPTI) Selinexor is approved for 5th line Multiple Myeloma and is currently being tested in other diseases. They have a […]

064 – Moderna Presents LAUGHABLE Interim Vaccine Data. Verastem Shows Mixed Success in Solid Tumors

Moderna Tx announced their first data from MRNA-1273 as a vaccine for SARS-CoV-2. In this video, I breakdown the press release and talk about how they missed the mark with providing only descriptive information. I then talk about Verastem Oncology (#VSTM), a company looking to treat cancer. Their one approved asset, Copiktra, is indicated for […]

063 – Biotech Updates (Including NASH follow up) STML TGTX SAVA SRNE TRIL MRKR GNFT CBAY

Hey everybody! In this video, I catch up on a variety of biotech companies. Timestamps for the respective company are below:STML 2:44TGTX 4:29SAVA 6:27SRNE 11:27TRIL/MRKR 15:15GNFT/CBAY 20:55 If you want to help the show, you can donate here: https://tips.pinecast.com/jar/breaking-biotechYou can also open an account at Tastyworks using my referral code here: https://start.tastyworks.com/#/login?referralCode=ZWQ77XG2PZ Follow me on […]

062 – Treatments from Gilead and Regeneron Move Forward in Battle Against COVID-19!

Gilead’s (#GILD) Remdesivir shows mixed results in 4 separate studies looking at treating COVID-19. The NIAID study has the most promise with a slight benefit in survival and significant benefit in time to recovery. Regeneron’s (#REGN) Kevzara on the other hand, has now been limited to “critical” COVID-19 patients and we should see a phase […]

061 – Gilead’s Remdesivir Efficacy Still Uncertain! Is Stemline Therapeutics a Buy?

In this video, I talk about the New England Journal of Medicine study published by Gilead (#GILD) on the compassionate use of Remdesivir for COVID-19. I also touch on the Statnews article about the leaked information regarding their upcoming Phase 3 trials. Finally, I talk about a great buying opportunity in the company Stemline Therapeutics […]

060 – Amarin Loses Vascepa Exclusivity in USA. Athersys Pivots to COVID-19.

The District Court of Nevada rules that Amarin’s Vascepa patents are invalid, but an appeal has already been filed! Axsome therapeutics fails their Phase 3 trial in treatment-resistant depression, but plans on moving forward with another trial. Finally, I talk about Athersys and their Multistem Cell Therapy for Acute Respiratory Distress Syndrome after receiving a […]